- 08 Dec 2022
- ICICIdirect Research
OZEMPIC, WEGOVY, NOVO NORDISK DRUG, STILL OUT OF REACH FOR MANY INDIAN CONSUMERS
News:
The oral form of these drugs was granted an approval in India by the Central Drugs Standard Control Organisation under the brand name Rybelsus, to treat type 2 diabetes in 2020, and had hit the Indian markets in January 2022. While Ozempic (1 mg once weekly) was approved primarily for diabetes, approval for Wegovy injection (2.4 mg once weekly) came for overweight adults with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Many Indian consumers are still finding it expensive due to its higher pricing, which keeps it out of reach
View:
We expect some in-licensing deals to take place in due course where pricing can be brought within the reach. If that happens, we expect obesity as a new target category in future. Many companies can strike licensing deals in future
Impact:
Positive